Assenagon Asset Management S.A. Concert Pharmaceuticals, Inc. Transaction History

Assenagon Asset Management S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 12, 2023	SELL	$4.34 - $5.84 $610,004 - $820,835	-140,554 Reduced 15.45%	769,336 $4.49 Million
Q3 2022 Oct 27, 2022	BUY	$4.27 - $7.2 $1.54 Million - $2.6 Million	361,047 Added 65.78%	909,890 $6.1 Million
Q2 2022 Jul 27, 2022	BUY	$2.8 - $6.36 $1.45 Million - $3.29 Million	516,912 Added 1618.84%	548,843 $2.31 Million
Q1 2022 Apr 25, 2022	SELL	$2.73 - $3.94 $300,390 - $433,530	-110,033 Reduced 77.51%	31,931 $108,000
Q4 2021 Feb 01, 2022	SELL	$2.69 - $4.22 $253,944 - $398,380	-94,403 Reduced 39.94%	141,964 $447,000
Q3 2021 Oct 19, 2021	BUY	$3.17 - $4.15 $300,138 - $392,926	94,681 Added 66.82%	236,367 $773,000
Q2 2021 Jul 15, 2021	BUY	$3.77 - $5.24 $59,015 - $82,026	15,654 Added 12.42%	141,686 $598,000
Q1 2021 Apr 26, 2021	BUY	$4.86 - $13.07 $612,515 - $1.65 Million	126,032 New	126,032 $629,000
Q3 2019 Oct 16, 2019	SELL	$5.88 - $12.35 $644,377 - $1.35 Million	-109,588 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$9.44 - $13.12 $1.03 Million - $1.44 Million	109,588 New	109,588 $1.32 Million

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.